Inhibiteurs de tyrosine kinase ciblant le VEGFR

Angiogenesis is a key mechanism in tumour growth and metastasis. The vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) family is one of the most important angiogenesis regulators. Different agents that target the VEGF and VEGFR pathway at various developmental stages of a large number of solid tumours are currently being investigated. VEGFR tyrosine kinase inhibitors are small molecules that bind to the active site of ATP in the VEGFR tyrosine kinase domain, blocking intracellular signaling. Phase II and III of the growth of different solid tumours (kidney cancer, stromal and lung tumours, melanoma, hepatocellular carcinoma, and others) are appropriate for studying the effectiveness of sorafenib, sunitinib, and other agents, such as valatinib and ZD6474. Randomized trials studying phase III have already demonstrated the effectiveness of sorafenib and sunitinib in treating kidney cancer metastasis and stromal tumours.